Copper carve-outs
Teck Resources (TECK) and Kodiak Copper (KDKCF) outlined plans to spin U.S.-focused copper projects into a new company. Both stocks were flat, which fits. Spin headlines don’t move tape until investors can model the package: which assets go in, what stays behind, who owns what, who writes the checks, who runs it, and how long the regulatory grind takes.
The strategy is straightforward. Copper remains the cleanest “electrification + data center power buildout” lever, and supply is still constrained by timelines and permitting more than by geology or price. The U.S.-domiciled angle also lines up with critical-minerals policy tailwinds, but the market isn’t paying for vibes. Until the terms show this is a real, financeable pure-play—and not a shuffle of assets with a fresh logo—it stays in the “call me when you have numbers” bucket.
Biotech IPO tape
The clearest risk-on signal wasn’t the index. It was new issuance that actually worked.
Avalyn Pharma (AVLN) priced a $300 million IPO and traded +44% on day one. That kind of pop isn’t the market solving the science in an afternoon. It’s tight allocations, a clean float, and generalists who are underweight biotech trying to get exposure without chasing thin secondary names. When deals open like that, the window doesn’t just crack—it starts getting tested.
Hemab Therapeutics (HEMAB) traded up after increasing the proposed IPO size to 15 million shares. Upsizing usually means the order book could take more supply without breaking. The real test is pricing discipline and the next two weeks of trading, but it’s still a constructive tell.
A functioning IPO tape matters because it gives portfolios another way to express risk besides piling into the same mega-cap liquidity. In this setup, returns can come from scarcity and deal mechanics—not just index flow.
AI: winners and bill payers
AI exposure keeps splitting into “benefit now” versus “spend now.”
Caterpillar (CAT) surged after an earnings beat, with commentary tying strength to AI-related power demand, marking its biggest gain in six months. The market’s AI lens keeps widening: not just chips and cloud contracts, but the physical buildout—power equipment, construction, grid work, redundancy. CAT turned that into near-term numbers and got paid. Throughput and orders beat narrative.
Microsoft (MSFT) moved the other way as higher AI spending overshadowed strong cloud performance and Copilot adoption. Same macro story, different math. Investors are leaning harder on capex intensity, margins, and free-cash-flow timing, even when product metrics look good. The tape treated it as “great franchise, expensive quarter.”
Bottom line: AI isn’t one factor anymore. The market is separating names that can book earnings now from names asking you to fund the buildout and wait.
Rates and steady corporates
Macro leaned rate-sensitive: 30-year mortgage rates ticked up to 6.3%. Not a shock print, but housing still trades on inches, and higher rates keep the group in “stabilize” mode.
Policy language didn’t help either. The Fed signaled a surprise shift around rate cuts, and that kind of messaging tends to widen duration risk premia and push leadership back toward cash-flow stories.
A few corporates delivered simple, legible signals:
- Intercontinental Exchange (ICE) rose after hiking its dividend 8% to $0.52/share. Steady cash generation, higher return of capital.
- Alnylam reaffirmed 2026 TTR sales guidance of $4.4B–$4.7B and expanded trial enrollment to ~1,750 patients. Long-dated guideposts matter more when the biotech window is open.
- Service Corporation International reaffirmed 2026 normalized EPS of $4.05–$4.35 while projecting funeral volume down 1%–3%. Defensives are being held for margin durability, not growth.
Virgin Galactic (SPCE) bouncing after six straight down days was just that: a bounce, not a thesis.
The day’s tell was simple: risk appetite showed up where capital had to commit—new biotech paper and real-economy AI demand—while the market stayed picky about who’s earning now versus who’s still paying the bill.